Jerusalem, Israel

Nir Sharon

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2018

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Nir Sharon

Introduction

Nir Sharon is a notable inventor based in Jerusalem, Israel. He has made significant contributions to the field of medical science, particularly in the prevention of ischemia reperfusion injury (IRI) in organs. His work is crucial for improving outcomes in organ transplantation and treatment.

Latest Patents

Nir Sharon holds a patent for "Methods and compositions for preventing ischemia reperfusion injury in organs." This invention focuses on compounds and methods aimed at preventing IRI, especially in organs aged 35 years and older. The patent outlines specific uses, including the prevention of IRI in native organs in vivo, reimplantations, and transplantations of donor organs. Additionally, it addresses the prophylaxis of delayed graft function and aims to reduce the frequency, amount, and duration of dialysis in recipients of deceased donor kidney transplantations. The methods involve contacting the organ in vivo or ex vivo with a temporary p53 inhibitor, and novel temporary dsNA p53 inhibitors are also provided.

Career Highlights

Nir Sharon is associated with Quark Pharmaceuticals, Inc., where he continues to advance his research and innovations. His work is pivotal in the development of therapies that enhance organ viability and function.

Collaborations

Nir has collaborated with esteemed colleagues, including Elizabeth C. Squiers and Shai Erlich, contributing to a dynamic research environment that fosters innovation.

Conclusion

Nir Sharon's contributions to the field of organ transplantation and ischemia reperfusion injury prevention are invaluable. His innovative approaches and collaborations continue to pave the way for advancements in medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…